The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
December 8th 2024
The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).
Oncology Pharmacy: The Need for Specialization in Specialty Pharmacy
May 19th 2014The complexities of cancer and the ever-changing medication regimens employed in its treatment call for the specialized competencies of oncology-focused pharmacies. High-touch care and oncology expertise can improve outcomes.
Read More
Predicting Cardiotoxicity Before it Happens in Patients with Breast Cancer
March 18th 2014Using a very high sensitivity assay analyzing changes in levels of MPO and troponin I before, and 3 months after starting a chemotherapy regimen, investigators were able to predict 46.5% of cases of chemotherapy-associated cardiotoxicity before they occurred.
Read More
Uncloaking Tumor Cells With Programmed-Death Receptor-1 Inhibitors
February 14th 2014Scientists are using monoclonal antibodies to help the body fight off tumors in the same way that the body fights off infections. Monoclonal antibodies that target the interaction of programmed-death receptor-1 (PD-1) on T cells and its ligand (PD-L1) on tumor cells. Merck's MK-3475 prevents the interaction of PD-1 and PD-L1, thereby inhibiting a mechanism by which some tumors avoid immune detection.
Read More
Anesthesia-Analgesia Combination for Prostate Cancer Surgery May Improve Outcomes
January 10th 2014Patients who received lower levels of opioid painkillers due to use of neuraxial analgesia along with general anesthesia had lower levels of systematic progression and overall death than those who received general anesthesia alone.
Read More